Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 1184 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Semaglutide for overweight individuals	ATB200/AT2221 , Semaglutide (Ozempic)	Obesity , Weight management	Endocrine Nutritional and Metabolic Disorders	2020	View \| Download
Semaglutide for treating obesity-related heart failure	Semaglutide (Ozempic)	Obesity-related heart failure	Cardiovascular System , Endocrine Nutritional and Metabolic Disorders	2022	View \| Download
Semaglutide for treating overweight and obesity	Semaglutide (Ozempic)	Obesity	Endocrine Nutritional and Metabolic Disorders	2022	View \| Download
Semaglutide for treating overweight and obesity in adolescents ages 12 to 17 years old	Semaglutide (Ozempic)	Obesity	Endocrine Nutritional and Metabolic Disorders	2022	View \| Download
Semaglutide for treating overweight or obesity with cardiovascular disease	Semaglutide (Ozempic)	Cardiovascular disease (CVD) , Obesity	Cardiovascular System , Endocrine Nutritional and Metabolic Disorders	2023	View \| Download
Semaglutide for treating peripheral arterial disease (PAD) and type 2 diabetes	Semaglutide (Ozempic)	Peripheral arterial disease (PAD) , Type 2 diabetes	Cardiovascular System , Endocrine Nutritional and Metabolic Disorders	2022	View \| Download
Serplulimab with chemotherapy for treating previously untreated extensive stage small-cell lung cancer	Serplulimab (HLX10)	Small-cell lung cancer (SCLC)	Lung and Respiratory Cancer	2023	View \| Download
Setmelanotide for obesity in Bardet-Biedl syndrome and Alstrom syndrome	Setmelanotide (RM-493)	Hyperphagia , Obesity	Endocrine Nutritional and Metabolic Disorders , Gastroenterology , Genetic Disorders	2021	View \| Download
Setmelanotide for pro-opiomelanocortin deficiency obesity	Setmelanotide (RM-493)	Obesity due to pro-opiomelanocortin deficiency	Endocrine Nutritional and Metabolic Disorders	2017	View \| Download
Setmelanotide for rare genetic obesity due to leptin receptor deficiency	Setmelanotide (RM-493)	Obesity due to Leptin receptor deficiency	Endocrine Nutritional and Metabolic Disorders	2019	View \| Download